<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Reported-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM25940-G9C-RR-5FH"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 S2292 RS: Over-the-Counter Monograph Drug User Fee Amendments</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-09-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><calendar>Calendar No. 152</calendar><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 2292</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250715">July 15, 2025</action-date><action-desc><sponsor name-id="S429">Mr. Banks</sponsor> (for himself, <cosponsor name-id="S362">Mr. Kaine</cosponsor>, <cosponsor name-id="S426">Mr. Kim</cosponsor>, and <cosponsor name-id="S438">Mr. Husted</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00" added-display-style="italic" deleted-display-style="strikethrough">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><action stage="Reported-in-Senate"><action-date date="20250908">September 8, 2025</action-date><action-desc>Reported by <sponsor name-id="S373">Mr. Cassidy</sponsor>, with an amendment</action-desc><action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="HDC9190379A3D428AB2AE64881C57F1A9"><section section-type="section-one" id="HAD86D77B7ADA40019F6677DC067B063E" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>.</text></section><section id="HD66F4AF206B04B428243984AF15ECC43" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>2.</enum><header>Finding</header><text display-inline="no-display-inline">Congress finds that the fees authorized by the amendments made in this Act will be dedicated to OTC monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate, as set forth in the Congressional Record.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="H4B2044A874E243F39AA93933C768851E" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>3.</enum><header>Definitions</header><text display-inline="no-display-inline">Section 744L(9)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71(9)(A)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="HB2D5437039254551A9E111F981313DBB"><enum>(1)</enum><text>in clause (v), by striking <quote>; or</quote> and inserting a semicolon;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H58E17AB7F6BB41FBB5569125C86A62EA"><enum>(2)</enum><text>in clause (vi)—</text><subparagraph id="H3CBF095DB323492CBA0DE6E7C532645E"><enum>(A)</enum><text>by striking <quote>addition</quote> and inserting <quote>the addition</quote>; and</text></subparagraph><subparagraph id="H7021D4A8E96649D2B4D0741846B317D7"><enum>(B)</enum><text>by striking the period and inserting <quote>; or</quote>; and</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H0247DABD8CD04CCBAE2204FFD4CEE94F"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HFE947706813B418C850500BF5D07FCFE" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><clause id="H89BA1E788E744986948C0120EDAADCA6" indent="up1"><enum>(vii)</enum><text>the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—</text><subclause id="H942ADF6E0A5C431AADBC9CF5DC3E100F"><enum>(I)</enum><text>established by a national or international standards development organization; and</text></subclause><subclause commented="no" id="H3479C08D9C6A453A8CB4BCA5713CF6BE"><enum>(II)</enum><text display-inline="yes-display-inline">recognized by the Secretary through a process described in guidance for industry, initially published in July 2023, or any successor guidance, publicly available on the website of the Food and Drug Administration, which addresses voluntary consensus standards for pharmaceutical quality.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="H8EC38B552B334E019A85CAED8B7BF1C5" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>4.</enum><header>Authority to assess and use OTC monograph fees</header><subsection commented="no" display-inline="no-display-inline" id="HAD0F4D881B314F5F8A1111033BDCBD30"><enum>(a)</enum><header display-inline="yes-display-inline">Types of fees</header><text display-inline="yes-display-inline">Section 744M(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(a)(1)</external-xref>) is amended—</text><paragraph id="H6B9055FF68F94296B2AC620A80C35A9C"><enum>(1)</enum><text>in subparagraph (A)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HF8FBDFD4EC104757991BDB5874331400"><enum>(A)</enum><text>by striking <quote>on December 31 of the fiscal year or at any time during the preceding 12-month period</quote> and inserting <quote>at any time during the applicable period specified in clause (ii) for a fiscal year</quote>;</text></subparagraph><subparagraph id="H3DBF936644814FA3A13FCF5F8B797058"><enum>(B)</enum><text>by striking <quote>Each person</quote> and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7E3FD6C589A34E7C95A9E22EF2F079D7" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><clause id="HD14ED13069CD48C893319A7CAF30B827"><enum>(i)</enum><header>Assessment of fees</header><text>Each person</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HA733BD79E3AC4D1DA5201034199B5E41"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H16DCF6DC306241D0AA967A02B2421407" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><clause id="H72BB1EDFA5F642D5949047C8750DBF46"><enum>(ii)</enum><header>Applicable period</header><text>For purposes of clause (i), the applicable period is— </text><subclause commented="no" display-inline="no-display-inline" id="HDFC39F0E23FF4184A124249A200DF5B4"><enum>(I)</enum><text display-inline="yes-display-inline">for fiscal year 2026, the 12-month period ending on December 31, 2025; </text></subclause><subclause id="H3296D8FC89124B7E9199130DE4A116CF"><enum>(II)</enum><text>for fiscal year 2027, the 9-month period ending on September 30, 2026; and</text></subclause><subclause id="H6B71B80B28E14E59AAA89CAF807A6C87"><enum>(III)</enum><text>for fiscal year 2028 and each subsequent fiscal year, the 12-month period ending on September 30 of the preceding fiscal year.</text></subclause></clause><after-quoted-block>; </after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H391950034DBB4FCDA08D52120915072E"><enum>(2)</enum><text>in subparagraph (B)(i), by amending subclause (I) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H2B7070689E564482AE14ECE395BB3E96" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><subclause id="H7FC10EF28F37476982B253C49A3F0515"><enum>(I)</enum><text>has ceased all activities related to OTC monograph drugs prior to—</text><item commented="no" display-inline="no-display-inline" id="H9FC208717D154339A4F774A23B839878"><enum>(aa)</enum><text>for purposes of fiscal year 2026, January 1, 2025;</text></item><item commented="no" display-inline="no-display-inline" id="H15D6B9305EBC4CF5BA0F88E4D7AB5EC4"><enum>(bb)</enum><text>for purposes of fiscal year 2027, January 1, 2026; and</text></item><item commented="no" display-inline="no-display-inline" id="H1BBCC5CEFFAD4ED8B50127AEDE74E7FC"><enum>(cc)</enum><text>for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and</text></item></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="HE7D37D67EC6D4003970F4CB6F03AD0D5"><enum>(3)</enum><text>by amending subparagraph (D) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HE6E6BFC79E25491B876075CDB7DB351C" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><subparagraph id="H6180D7A03A234728B2F97A9B15F368CD"><enum>(D)</enum><header>Due date</header><clause commented="no" display-inline="no-display-inline" id="HC347486B87DD4C519597F971FE1897B6"><enum>(i)</enum><header>Fiscal year 2026</header><text>For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause commented="no" display-inline="no-display-inline" id="H3AA830A3946C41CCB60AC3A558AB8A4B"><enum>(I)</enum><text display-inline="yes-display-inline">the first business day of June of such year; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H54BC806214CF455FA85C23B06BF247D3"><enum>(II)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H4621189D57D34BDA9CE01D33B119FD5D"><enum>(ii)</enum><header>Fiscal year 2027</header><text>For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—</text><subclause commented="no" display-inline="no-display-inline" id="H78DAD30D3AAC4E02AC76D2281858942A"><enum>(I)</enum><text>in a first installment representing 50 percent of such fee, on the later of—</text><item commented="no" display-inline="no-display-inline" id="HD73BD642CC4F4427A1201944B5554732"><enum>(aa)</enum><text display-inline="yes-display-inline">October 1, 2026; or </text></item><item id="H137414E090F34915B2754279C314EDB4"><enum>(bb)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year; and</text></item></subclause><subclause commented="no" display-inline="no-display-inline" id="H4C5E3FF0F1B740C59FD4AE7AB3DB785D"><enum>(II)</enum><text display-inline="yes-display-inline">in a second installment representing the remaining 50 percent of such fee, on—</text><item id="HED0B96677FBD4636B77AEDEA1F55705D"><enum>(aa)</enum><text>February 1, 2027; or</text></item><item id="HAC186950D01A4425B6E7E42FD53C2A5C"><enum>(bb)</enum><text>if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.</text></item></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HD977548751D84BB6BA35129A631D490B"><enum>(iii)</enum><header>Subsequent fiscal years</header><text>For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause id="H8B5E1F423D7B45EEA17D3084B79E958F"><enum>(I)</enum><text>the first business day on or after October 1 of the fiscal year; or</text></subclause><subclause id="H4D8E7CDD91B04EEC840CEA7BDE4EBC4B"><enum>(II)</enum><text>the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees under this section for the fiscal year.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H6D7CE99AD7674E45BA7383C299AC2B13"><enum>(b)</enum><header>Fee revenue amounts</header><text>Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(b)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HAC3C690A106F444EA569D0F38601640D" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><subsection commented="no" display-inline="no-display-inline" id="HA8C4985C957B4EA8BCBFBF6BD3532DC4"><enum>(b)</enum><header display-inline="yes-display-inline">Fee revenue amounts</header><paragraph id="HF773D33750D74A7DA610F97D5D1D2A71"><enum>(1)</enum><header>In general</header><text>For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—</text><subparagraph id="HCF78DEB2E6924614A565C37DE2CB2399"><enum>(A)</enum><text>the annual base revenue for the fiscal year (as determined under paragraph (2));</text></subparagraph><subparagraph id="HB66B0DACE1C4440D8152B67D780F65A6"><enum>(B)</enum><text>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));</text></subparagraph><subparagraph id="HDA01D04B502A4501B32CEAF1C48F9AC1"><enum>(C)</enum><text>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2));</text></subparagraph><subparagraph id="H09D598FB50E5442197EDA821A7BD35D6"><enum>(D)</enum><text>additional direct cost adjustments (as determined under subsection (c)(3));</text></subparagraph><subparagraph id="H30BDF63957514F2A8263DC687E31F751"><enum>(E)</enum><text>an additional dollar amount equal to—</text><clause id="H1249E6DCF7D441938141359AA4530218"><enum>(i)</enum><text>$2,373,000 for fiscal year 2026;</text></clause><clause id="H81C8476F533545A094E4AD58C8BB0755"><enum>(ii)</enum><text>$1,233,000 for fiscal year 2027; and</text></clause><clause id="H106948A597C44FF4B60CB076C8AC8C09"><enum>(iii)</enum><text>$854,000 for fiscal year 2028; and</text></clause></subparagraph><subparagraph id="HF204F422BA194843B540BB6D20C22F16"><enum>(F)</enum><text>in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.</text></subparagraph></paragraph><paragraph id="H0471BB9E0F7749ECA9486C412CC965AD"><enum>(2)</enum><header>Annual base revenue</header><text>For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—</text><subparagraph id="H683DF88313F446B2BDE1B8BC64FB470E"><enum>(A)</enum><text>for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before the date of enactment of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title>, not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and</text></subparagraph><subparagraph id="H7F71731372914C428FF5F944FC5A461C"><enum>(B)</enum><text>for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HDF45863D1D9F461F85CE548659F5FD64"><enum>(c)</enum><header>Adjustments; annual fee setting</header><text>Section 744M(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="HBFED8B21DD154CFB98A50F11EEEA547E"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H6D38622FF10D4DC491DA83DD9DE5DACE"><enum>(A)</enum><text>in subparagraph (A), in the matter preceding clause (i)—</text><clause commented="no" display-inline="no-display-inline" id="H61618A9285FF4430B8740FDB6D6AC8FE"><enum>(i)</enum><text>by striking <quote>subsection (b)(2)(B)</quote> and inserting <quote>subsection (b)(1)(B)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H9F7BFE1C0B564A60B7435EF6C2D9FB15"><enum>(ii)</enum><text>by striking <quote>fiscal year 2022 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H9138650900824BF9AD53092359BAF848"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking <quote>fiscal year 2022</quote> and all that follows through the period at the end and inserting the following:</text><quoted-block style="OLC" display-inline="yes-display-inline" id="H2581C8E77CD54F728371A938639BD3D2" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><text>a fiscal year shall be equal to the product of—</text><clause id="HBA899D2E58254AD88DA485F864074750"><enum>(i)</enum><text>for fiscal year 2026—</text><subclause commented="no" display-inline="no-display-inline" id="H159954A9609844708D597D39CF793D85"><enum>(I)</enum><text>the fee for fiscal year 2025 under subsection (a)(2); and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HA5F73A9D1F204F69BB403A3DE5DFE008"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C); and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H942F7C4F176D45DBBB61A5393B015513"><enum>(ii)</enum><text display-inline="yes-display-inline">for each of fiscal years 2027 through 2030—</text><subclause commented="no" display-inline="no-display-inline" id="HF381BBAC5F2C48749B51CBC237DF60D6"><enum>(I)</enum><text display-inline="yes-display-inline">the applicable fee under subsection (a)(2) for the preceding fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H8C503B4C3DF24E9FB55C36CAC8DA2543"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C).</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H74D1B84D54864F3EB57548038170601E"><enum>(C)</enum><text>in subparagraph (C)—</text><clause commented="no" display-inline="no-display-inline" id="HC2105EFAD7974F9C9FD121C8A3F43731"><enum>(i)</enum><text>in the matter preceding clause (i), by inserting <quote>the sum of</quote> after <quote>is equal to</quote>;</text></clause><clause commented="no" display-inline="no-display-inline" id="H0B0A9BD98E3B419ABA90EF101698812A"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking clause (i);</text></clause><clause commented="no" display-inline="no-display-inline" id="HD74225CE74E945C6A8418DDC87DA46D3"><enum>(iii)</enum><text>by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;</text></clause><clause commented="no" display-inline="no-display-inline" id="H86856E5CDB8C4B1592042E14F699A522"><enum>(iv)</enum><text>by striking <quote>(ii) for each of fiscal years 2024 and 2025, the sum of—</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H97C8428383384466A79864B74AB44A0E"><enum>(v)</enum><text>in clause (ii), as so redesignated, by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington–Arlington–Alexandria–DC–VA–MD–WV</quote>;</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H7CEF534407CA477CB4B7A7E067C6328A"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H5BC6315B43F241D58208443C1AD76B62"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text><clause commented="no" display-inline="no-display-inline" id="H4A628D2D2FDE47088970D6B833B4B163"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>fiscal year 2021 and subsequent fiscal years</quote> and inserting <quote>each fiscal year</quote>;</text></clause><clause commented="no" display-inline="no-display-inline" id="H0FD60FA1BAE54ED6BD61E8D1BE6BABFB"><enum>(ii)</enum><text>by striking <quote>subsections (b)(1)(B) and (b)(2)(C)</quote> and inserting <quote>subsection (b)(1)(C)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H97E0BB0AF4D44940B59C9A28E068A35A"><enum>(iii)</enum><text>by striking <quote>the number of weeks specified in subparagraph (B)</quote> and inserting <quote>10 weeks</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H520254E0FFB74F1FBC61CD4BCBE73AA8"><enum>(B)</enum><text>by striking subparagraph (B);</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H4D26A29051D545638FA82A11236250CD"><enum>(C)</enum><text>by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H88A4BB9E9A944729A4CF05472BF57D4F"><enum>(D)</enum><text>in subparagraph (C), as so redesignated, by striking <quote>paragraph (4) establishing</quote> and inserting <quote>paragraph (5) publishing</quote>;</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H81E497F6DE7A4E2EB8E392F34037106A"><enum>(3)</enum><text>in paragraph (3)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H420B4B322C97492E8D47534780EF51AB"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A), by striking <quote>subsection (b)(2)(D)</quote> and inserting <quote>subsection (b)(1)(D)</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H54290A7769B6456DB8E306FDCA647C00"><enum>(B)</enum><text>by striking subparagraphs (A) through (E) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HEC9E49DC71ED4A73962DD03009A5573C" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><subparagraph id="H83124516D4C5464F9F0FA060A3516F93"><enum>(A)</enum><text>$135,000 for fiscal year 2026;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H598C9911DB1C4667AF84FEB45E95FA91"><enum>(B)</enum><text>$300,000 for fiscal year 2027;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H2888A0F1B0404ECFA01F716F0E2F7CC9"><enum>(C)</enum><text>$55,000 for fiscal year 2028;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H90ED35443C6E4AFAA9224E0F6E56C40B"><enum>(D)</enum><text>$30,000 for fiscal year 2029; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H95BF80BEABF048F6ABC449E47052E1A0"><enum>(E)</enum><text>$0 for fiscal year 2030.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1CDB4372FBED43A7B7687E5140EA7B10"><enum>(4)</enum><text>by striking paragraph (4) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H49FB3DA482CB4459A2CB737FE64A3B75" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><paragraph id="H46539925A1674F969E318126ADE934B6"><enum>(4)</enum><header>One-time facility fee workload adjustment</header><subparagraph commented="no" display-inline="no-display-inline" id="HC8A19F03556F42F380FA95211185222F"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text>In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H58263C51C01C457BA81680CFB540AE71"><enum>(B)</enum><header>Adjustment described</header><clause commented="no" display-inline="no-display-inline" id="H242E580F85D9415E996A1B956FAE8D16"><enum>(i)</enum><header>Conditions for adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph may be made for a fiscal year only if—</text><subclause commented="no" display-inline="no-display-inline" id="H2EFC3E52C1A54B79AC2FACD7D73C86D1"><enum>(I)</enum><text display-inline="yes-display-inline">an adjustment under this paragraph had not been made for any prior fiscal year;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H88588118C20A40C8B69278BBF59CE2CE"><enum>(II)</enum><text display-inline="yes-display-inline">the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HE5CAB46CAEBB418E813EF7F1A4C283D6"><enum>(III)</enum><text display-inline="yes-display-inline">with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H0A10AE2B51A340E4B8C0C0033DBEF480"><enum>(ii)</enum><header>Amount of adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph for a fiscal year shall equal the product of—</text><subclause commented="no" display-inline="no-display-inline" id="H286CEEF829A149EBA683A5CD61B7ACC2"><enum>(I)</enum><text display-inline="yes-display-inline">the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HE379AEF55D6E4F8C981236B6DFF45571"><enum>(II)</enum><text display-inline="yes-display-inline">the excess facility percentage described in clause (iii).</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HEC23AE3D54074AA987C8DA45BDA9D0C9"><enum>(iii)</enum><header>Excess facility percentage</header><text display-inline="yes-display-inline">The excess facility percentage described in this clause is—</text><subclause commented="no" display-inline="no-display-inline" id="HEAF275E62DF04020A2525B0C1B3E1A86"><enum>(I)</enum><text display-inline="yes-display-inline">the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HDBC6F3B53F264EA48E88667B1A584970"><enum>(II)</enum><text display-inline="yes-display-inline">1,625.</text></subclause></clause></subparagraph></paragraph><paragraph display-inline="no-display-inline" id="HD7F53375752745CAA6C6F09B1F3D6800"><enum>(5)</enum><header>Annual fee setting</header><text>The Secretary shall, not later than 60 days before the first day of each fiscal year—</text><subparagraph commented="no" display-inline="no-display-inline" id="HA4BBE1398E8E4DF5BC186E3573155846"><enum>(A)</enum><text>establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—</text><clause commented="no" display-inline="no-display-inline" id="H1F5ED7DDC74F4A96AECF8FF4B6E67E01"><enum>(i)</enum><text display-inline="yes-display-inline">OTC monograph drug facility fees under subsection (a)(1); and</text></clause><clause commented="no" display-inline="no-display-inline" id="HBA12135823664E6784344412CBCEC060"><enum>(ii)</enum><text>OTC monograph order request fees under subsection (a)(2); and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5F5E149B35FD437FBF48DFC7E55E7FEC"><enum>(B)</enum><text display-inline="yes-display-inline">publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H407163CDBDFB4ED2BFD458C1B74DA8D5"><enum>(d)</enum><header>Crediting and availability of fees</header><text>Section 744M(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(f)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="HBAB4E92E135E4796AFC599D7365D7F55"><enum>(1)</enum><text>in paragraph (2)(D)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HD41D3D4F40D04206A0F4BB567F7659C8"><enum>(A)</enum><text>in the subparagraph heading, by striking <quote><header-in-text level="subparagraph" style="OLC">in subsequent years</header-in-text></quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H22F79B086EAB4264AD156187538BDDAA"><enum>(B)</enum><text>by striking <quote>(after fiscal year 2021)</quote>; and</text></subparagraph></paragraph><paragraph id="H8E112A0BC1CB40788DF4583F36727656"><enum>(2)</enum><text>in paragraph (3), by striking <quote>2021 through 2025</quote> and inserting <quote>2026 through 2030</quote>.</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="H8B16CA9BA9DF49DDA439CB35CBC88377" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>5.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H54BDF69CAE314C76BF2CF282B843D3D1"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H00B16E666ACE40CF9F605D97BD8CEA12"><enum>(A)</enum><text>by striking <quote>Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter</quote> and inserting <quote>Not later than 120 calendar days after the end of each fiscal year</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H3ED70894FD3D4813826D091409BE62F1"><enum>(B)</enum><text>by striking <quote>section 3861(b) of the CARES Act</quote> and inserting <quote>section 2 of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>;</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H62A08F87793A48529670FDB90E330E85"><enum>(2)</enum><text>in subsection (b), by striking <quote>fiscal year 2021 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H2EF8F5135B5E48D2BB080C4C67DFFF1E"><enum>(3)</enum><text>in subsection (d), by striking <quote>2025</quote> each place it appears and inserting <quote>2030</quote>.</text></paragraph></section><section commented="no" display-inline="no-display-inline" id="H454CA5BF718A44689D5A1FD0F044E12F" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>6.</enum><header>Sunset dates</header><subsection id="HF7D8F8FF08EA40B486E6EFF14C5E0AA0"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Sections 744L and 744M of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71</external-xref>; 379j–72) shall cease to be effective October 1, 2030.</text></subsection><subsection id="H3E6893AE29D246159646AFC0CFCFBF68"><enum>(b)</enum><header>Reporting requirements</header><text>Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) shall cease to be effective January 31, 2031.</text></subsection></section><section id="HC715728C7E1542DEBA9609A81FFB98CF" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>7.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this Act shall take effect on October 1, 2025, or the date of the enactment of this Act, whichever is later, except that fees under part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>) shall be assessed beginning October 1, 2025, regardless of the date of the enactment of this Act.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="HEBA5FC636425436F95D9B606673ABCAA" changed="deleted" reported-display-style="strikethrough" committee-id="SSHR00"><enum>8.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this Act, part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>), as in effect on the day before the date of enactment of this Act, shall continue to be in effect with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2026.</text></section></legis-body><legis-body style="OLC" display-enacting-clause="no-display-enacting-clause"><section section-type="section-one" id="idfac2cdf4-efc5-4d5a-abc1-9d8233600c92" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>.</text></section><section id="id0beb4bc1-4726-42c1-a4e4-4fdf20a0791b" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>2.</enum><header>Finding</header><text display-inline="no-display-inline">Congress finds that the fees authorized by the amendments made in this Act will be dedicated to OTC monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>) in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate, as set forth in the Congressional Record.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="id2c0a489f-7fae-46cc-b80a-9e59c5090800" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>3.</enum><header>Definitions</header><text display-inline="no-display-inline">Section 744L(9)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71(9)(A)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="idc7d140a7-8173-4e75-b9e2-8c302389818f"><enum>(1)</enum><text>in clause (v), by striking <quote>; or</quote> and inserting a semicolon;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9bb7ee01-030b-435f-a344-088862a00ac6"><enum>(2)</enum><text>in clause (vi)—</text><subparagraph id="id83ca5f0b-07bb-4c64-ac64-8fdf7e764047"><enum>(A)</enum><text>by striking <quote>addition</quote> and inserting <quote>the addition</quote>; and </text></subparagraph><subparagraph id="idd591dc95-727d-45ae-88f1-ea522ed50687"><enum>(B)</enum><text>by striking the period and inserting <quote>; or</quote>; and</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3e6cf19c-9f34-419a-ba44-ea9765764678"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id2d310bf6-b1e7-42f4-b151-81a368dfb2ce" changed="added" reported-display-style="italic" committee-id="SSHR00"><clause id="idb693887e-eff2-4884-b041-b2745d70c05f" indent="up1"><enum>(vii)</enum><text>the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—</text><subclause id="id778feb3b-858c-4f21-9174-37e45de0829f"><enum>(I)</enum><text>established by a national or international standards development organization; and</text></subclause><subclause commented="no" id="idaa42d441-9b77-4fe7-96ba-4e67c8aea641"><enum>(II)</enum><text display-inline="yes-display-inline">recognized by the Secretary through a process described in guidance for industry, initially published in July 2023, or any successor guidance, publicly available on the website of the Food and Drug Administration, which addresses voluntary consensus standards for pharmaceutical quality.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="idb0f4cfdd-b796-4a3f-a661-b7f217e4eed5" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>4.</enum><header>Authority to assess and use OTC monograph fees</header><subsection commented="no" display-inline="no-display-inline" id="ide4203d50-b97e-47c9-839b-74715638154b"><enum>(a)</enum><header display-inline="yes-display-inline">Types of fees</header><text display-inline="yes-display-inline">Section 744M(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(a)(1)</external-xref>) is amended—</text><paragraph id="id08ca2f90-d42b-4987-a13f-6e0c883e37ad"><enum>(1)</enum><text>in subparagraph (A)—</text><subparagraph commented="no" display-inline="no-display-inline" id="ide0333d5e-6880-4b62-be7c-f7ea69bbc690"><enum>(A)</enum><text>by striking <quote>on December 31 of the fiscal year or at any time during the preceding 12-month period</quote> and inserting <quote>at any time during the applicable period specified in clause (ii) for a fiscal year</quote>; </text></subparagraph><subparagraph id="idc57340ff-fa92-4ec6-b3b0-fa827cafbef0"><enum>(B)</enum><text>by striking <quote>Each person</quote> and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id2c516db0-532e-4edb-8061-f53d4c3e3729" changed="added" reported-display-style="italic" committee-id="SSHR00"><clause id="id68acca07-3dbe-4fdf-afb1-dd660c0675b5"><enum>(i)</enum><header>Assessment of fees</header><text>Each person</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc47cac1b-eab7-45b3-9cdd-a948e8740343"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id2e7cdbee-5fff-4adb-b196-fb30062e58fc" changed="added" reported-display-style="italic" committee-id="SSHR00"><clause id="id755edca9-fb4b-4fd0-ad9f-68e6b33a06d1"><enum>(ii)</enum><header>Applicable period</header><text>For purposes of clause (i), the applicable period is— </text><subclause commented="no" display-inline="no-display-inline" id="id12d4e242-1c83-456a-bbe2-a3134776fb25"><enum>(I)</enum><text display-inline="yes-display-inline">for fiscal year 2026, the 12-month period ending on December 31, 2025; </text></subclause><subclause id="idbcff92d8-9cbb-44ba-bec2-e6863d47ae03"><enum>(II)</enum><text>for fiscal year 2027, the 9-month period ending on September 30, 2026; and</text></subclause><subclause id="id1ccc3367-8f64-43ce-a4f9-3deb697c44f7"><enum>(III)</enum><text>for fiscal year 2028 and each subsequent fiscal year, the 12-month period ending on September 30 of the preceding fiscal year.</text></subclause></clause><after-quoted-block>; </after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="id228ea4e5-a190-4a02-b640-2e20ab0e31c8"><enum>(2)</enum><text>in subparagraph (B)(i), by amending subclause (I) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idd3f89348-4af3-4540-8df2-0c10b4814ffe" changed="added" reported-display-style="italic" committee-id="SSHR00"><subclause id="ided34eac8-5d3c-4a7f-8cc5-dae960548643"><enum>(I)</enum><text>has ceased all activities related to OTC monograph drugs prior to—</text><item commented="no" display-inline="no-display-inline" id="idebce09c0-0ac2-49fd-bac9-e45d6fd51da2"><enum>(aa)</enum><text>for purposes of fiscal year 2026, January 1, 2025;</text></item><item commented="no" display-inline="no-display-inline" id="id1c74b055-a4e3-4d8c-8c31-71d7d2eb2e76"><enum>(bb)</enum><text>for purposes of fiscal year 2027, January 1, 2026; and</text></item><item commented="no" display-inline="no-display-inline" id="id8a9f610d-8702-449e-85d3-6be3637be9b4"><enum>(cc)</enum><text>for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and</text></item></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="id681c78be-3ba3-4c34-ab56-0d7ff4edb6e2"><enum>(3)</enum><text>by amending subparagraph (D) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id4419e87a-e0d0-4a7d-8130-dccb5ef22662" changed="added" reported-display-style="italic" committee-id="SSHR00"><subparagraph id="ide95e4f9b-681f-4b8e-8061-d18821ad5ad6"><enum>(D)</enum><header>Due date</header><clause commented="no" display-inline="no-display-inline" id="id6d71ccda-1a88-41b7-9711-4f7debdcf266"><enum>(i)</enum><header>Fiscal year 2026</header><text>For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause commented="no" display-inline="no-display-inline" id="id176ee519-4535-46c6-984c-6decf2dccecb"><enum>(I)</enum><text display-inline="yes-display-inline">the first business day of June of such year; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idc1363931-3eb1-4808-80fe-c43d6ec88063"><enum>(II)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id13d73051-a707-44b7-8cd7-b65d0bd9091d"><enum>(ii)</enum><header>Fiscal year 2027</header><text>For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—</text><subclause commented="no" display-inline="no-display-inline" id="id8ef70f23-a9eb-47ab-abe0-26844a2e5f88"><enum>(I)</enum><text>in a first installment representing 50 percent of such fee, on the later of—</text><item commented="no" display-inline="no-display-inline" id="id1e338628-778d-4c46-b218-69073b27d7c8"><enum>(aa)</enum><text display-inline="yes-display-inline">October 1, 2026; or </text></item><item id="idd40565a5-17e2-445f-8fc7-a9ef192cb1d2"><enum>(bb)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year; and</text></item></subclause><subclause commented="no" display-inline="no-display-inline" id="id39cdeb07-5cbb-4f0f-8fa8-d792beec0336"><enum>(II)</enum><text display-inline="yes-display-inline">in a second installment representing the remaining 50 percent of such fee, on—</text><item id="id3f0ab48a-5e8a-4eb7-a6fb-6261af7b99d3"><enum>(aa)</enum><text>February 1, 2027; or</text></item><item id="idbda11684-43b8-4008-a681-8899acfad258"><enum>(bb)</enum><text>if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.</text></item></subclause></clause><clause commented="no" display-inline="no-display-inline" id="iddb76e82d-8111-40d4-9c08-43902e827067"><enum>(iii)</enum><header>Subsequent fiscal years</header><text>For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause id="id672cdeec-77f2-4c04-96d0-3801e529ab1f"><enum>(I)</enum><text>the first business day on or after October 1 of the fiscal year; or</text></subclause><subclause id="id1012fe8f-c093-4dea-a642-192c5edbe0a1"><enum>(II)</enum><text>the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees under this section for the fiscal year.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id7213a01e-25af-41eb-a514-fe4608b9c653"><enum>(b)</enum><header>Fee revenue amounts</header><text>Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(b)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id1c664fb1-5335-420d-8d9d-350029d1347d" changed="added" reported-display-style="italic" committee-id="SSHR00"><subsection commented="no" display-inline="no-display-inline" id="id70a2c1de-8b11-44b5-b7b6-1af31495328d"><enum>(b)</enum><header display-inline="yes-display-inline">Fee revenue amounts</header><paragraph id="id138e190e-7919-4da0-b2e7-20f0da9a7320"><enum>(1)</enum><header>In general</header><text>For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—</text><subparagraph id="id14dd2e71-8d74-43ff-b402-b52977e39769"><enum>(A)</enum><text>the annual base revenue for the fiscal year (as determined under paragraph (2));</text></subparagraph><subparagraph id="idc319f861-b2fa-4380-943b-031265639987"><enum>(B)</enum><text>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1)); </text></subparagraph><subparagraph id="id48879a55-f669-4361-b73f-40619094611f"><enum>(C)</enum><text>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2)); </text></subparagraph><subparagraph id="id8b18f3b6-5e56-415f-ae4b-811776a50c6a"><enum>(D)</enum><text>additional direct cost adjustments (as determined under subsection (c)(3));</text></subparagraph><subparagraph id="id7d8e2af4-044c-4cc7-a218-33264c4f6673"><enum>(E)</enum><text>an additional dollar amount equal to—</text><clause id="id1babef91-ede4-4563-ae32-655fd5d31450"><enum>(i)</enum><text>$2,373,000 for fiscal year 2026;</text></clause><clause id="idef8476c2-fe39-4cf8-8887-7948d1d45d9d"><enum>(ii)</enum><text>$1,233,000 for fiscal year 2027; and</text></clause><clause id="id95541fdc-d37f-4aea-8e79-9a84fecb179b"><enum>(iii)</enum><text>$854,000 for fiscal year 2028; and</text></clause></subparagraph><subparagraph id="id7b8625b0-c7d9-4fa9-b356-120790dbae46"><enum>(F)</enum><text>in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.</text></subparagraph></paragraph><paragraph id="id98186df7-bf8c-43a5-b53f-5107d591fc63"><enum>(2)</enum><header>Annual base revenue</header><text>For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—</text><subparagraph id="id0db43632-41e0-430d-b7d3-a661a6118c69"><enum>(A)</enum><text>for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before the date of enactment of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title>, not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and</text></subparagraph><subparagraph id="id93793c23-2019-40fa-b128-4b8e6f09e66f"><enum>(B)</enum><text>for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="id8c7aecc4-0ca1-485a-ad3f-77fb638863b6"><enum>(c)</enum><header>Adjustments; annual fee setting</header><text>Section 744M(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id8a8886b8-d69a-464a-8f0a-891201044129"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="id1dac362f-c08d-4014-9c3b-b2064fdc8887"><enum>(A)</enum><text>in subparagraph (A), in the matter preceding clause (i)—</text><clause commented="no" display-inline="no-display-inline" id="id47c50d88-8df2-428f-9456-d84db31ba840"><enum>(i)</enum><text>by striking <quote>subsection (b)(2)(B)</quote> and inserting <quote>subsection (b)(1)(B)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="idf01eaa1e-b65b-425d-a2d7-522766dd25a9"><enum>(ii)</enum><text>by striking <quote>fiscal year 2022 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id17278113-6885-4967-bb7a-e3b5a222cae7"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking <quote>fiscal year 2022</quote> and all that follows through the period at the end and inserting the following: </text><quoted-block style="OLC" display-inline="yes-display-inline" id="id36d7e08d-92fa-4315-b3c4-c41b9e99a9c2" changed="added" reported-display-style="italic" committee-id="SSHR00"><text>a fiscal year shall be equal to the product of—</text><clause id="id2f4de3bb-94d4-4107-b842-95a8da6ef0e3"><enum>(i)</enum><text>for fiscal year 2026—</text><subclause commented="no" display-inline="no-display-inline" id="id70ec3812-e7be-4685-9305-793150292d01"><enum>(I)</enum><text>the fee for fiscal year 2025 under subsection (a)(2); and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id204c865e-e832-4931-b76d-93e837a1de1b"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C); and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id12b69277-fb30-4686-a8e0-75a6cbce67db"><enum>(ii)</enum><text display-inline="yes-display-inline">for each of fiscal years 2027 through 2030—</text><subclause commented="no" display-inline="no-display-inline" id="idc3795c6d-a98b-4a03-89c5-0bf3755e3047"><enum>(I)</enum><text display-inline="yes-display-inline">the applicable fee under subsection (a)(2) for the preceding fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id95ab6717-b6da-4e76-b7fd-6ae92b7a1e80"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C).</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id92db714a-889b-4cb1-88f7-ecfd32ebd502"><enum>(C)</enum><text>in subparagraph (C)—</text><clause commented="no" display-inline="no-display-inline" id="idbd7de489-c318-4071-bd29-65464fd8f4d5"><enum>(i)</enum><text>in the matter preceding clause (i), by inserting <quote>the sum of</quote> after <quote>is equal to</quote>;</text></clause><clause commented="no" display-inline="no-display-inline" id="iddd887e10-fa5e-4d9d-a062-909b9ee22111"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking clause (i);</text></clause><clause commented="no" display-inline="no-display-inline" id="idae5c581e-d59e-47e2-bfe8-d0dc5993896f"><enum>(iii)</enum><text>by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly; </text></clause><clause commented="no" display-inline="no-display-inline" id="id8903666d-8239-42fc-8946-1f457fb6df11"><enum>(iv)</enum><text>by striking <quote>(ii) for each of fiscal years 2024 and 2025, the sum of—</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="idb6c116ef-4aee-4677-92b8-4705fde78a59"><enum>(v)</enum><text>in clause (ii), as so redesignated, by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington–Arlington–Alexandria–DC–VA–MD–WV</quote>;</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb23f5da5-5060-419d-9971-4b3b6d0d5b57"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph commented="no" display-inline="no-display-inline" id="iddd2b0de1-5ba7-4751-9ae6-c344f3511083"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text><clause commented="no" display-inline="no-display-inline" id="id98806010-25f9-4f7e-8be2-81794f2062b7"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>fiscal year 2021 and subsequent fiscal years</quote> and inserting <quote>each fiscal year</quote>; </text></clause><clause commented="no" display-inline="no-display-inline" id="id59a3dd10-552a-4e07-8e7a-5f12a621aa85"><enum>(ii)</enum><text>by striking <quote>subsections (b)(1)(B) and (b)(2)(C)</quote> and inserting <quote>subsection (b)(1)(C)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="id485fece5-ecbc-40e5-8ebd-ca0de8086b1c"><enum>(iii)</enum><text>by striking <quote>the number of weeks specified in subparagraph (B)</quote> and inserting <quote>10 weeks</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id25d7d4d5-8365-4499-8d73-75dbc6adfd74"><enum>(B)</enum><text>by striking subparagraph (B);</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idb2fe9312-8f54-46f0-9e38-7309e34cb9bd"><enum>(C)</enum><text>by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd11fa7cf-0ca4-43be-863a-e601fc157852"><enum>(D)</enum><text>in subparagraph (C), as so redesignated, by striking <quote>paragraph (4) establishing</quote> and inserting <quote>paragraph (5) publishing</quote>;</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idf6b29c54-fb27-49cd-93d0-5af0b6b441e3"><enum>(3)</enum><text>in paragraph (3)—</text><subparagraph commented="no" display-inline="no-display-inline" id="idec7060c7-ab5a-4bdf-aa32-d54da0634a16"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A), by striking <quote>subsection (b)(2)(D)</quote> and inserting <quote>subsection (b)(1)(D)</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id20e39990-5a00-44ac-9f2f-238f7b2dccef"><enum>(B)</enum><text>by striking subparagraphs (A) through (E) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id6115ffb4-ba39-42fc-a551-c50fee61431b" changed="added" reported-display-style="italic" committee-id="SSHR00"><subparagraph id="id65e5738b-8266-41c5-b041-c9273cab8822"><enum>(A)</enum><text>$135,000 for fiscal year 2026;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id40a99d3f-6bf4-42bc-9732-a91555fd6e12"><enum>(B)</enum><text>$300,000 for fiscal year 2027;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ida15e0ec9-c689-42f6-9474-c4e65a63ed20"><enum>(C)</enum><text>$55,000 for fiscal year 2028;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idda81ee7f-493e-4785-8232-3ca2291858b4"><enum>(D)</enum><text>$30,000 for fiscal year 2029; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3843805f-1388-4197-a896-483a8cc866c4"><enum>(E)</enum><text>$0 for fiscal year 2030.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id2272f882-9ce3-4acf-bf15-1d588b4c38f4"><enum>(4)</enum><text>by striking paragraph (4) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="ided156362-355e-451a-8c2d-18c656e381d6" changed="added" reported-display-style="italic" committee-id="SSHR00"><paragraph id="id248b7c98-a712-485c-a737-e3f2eed35342"><enum>(4)</enum><header>One-time facility fee workload adjustment</header><subparagraph commented="no" display-inline="no-display-inline" id="ideb46b5be-c8f1-4742-af61-2916d12518ee"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text>In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idecd7d7a2-8203-4f5e-af96-b241f65272fa"><enum>(B)</enum><header>Adjustment described</header><clause commented="no" display-inline="no-display-inline" id="ida5248d63-9f43-4a85-8c91-75f04d430f77"><enum>(i)</enum><header>Conditions for adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph may be made for a fiscal year only if—</text><subclause commented="no" display-inline="no-display-inline" id="idb0c67b51-d49e-48ab-b326-c8041ab69a47"><enum>(I)</enum><text display-inline="yes-display-inline">an adjustment under this paragraph had not been made for any prior fiscal year;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idfaa74bb7-eca3-4131-9fbb-597f7ca92dc2"><enum>(II)</enum><text display-inline="yes-display-inline">the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idd5065d1b-f045-46fd-9721-8491d8e5050c"><enum>(III)</enum><text display-inline="yes-display-inline">with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id02a7a26d-4c00-422d-82ee-ee325c00ddbd"><enum>(ii)</enum><header>Amount of adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph for a fiscal year shall equal the product of—</text><subclause commented="no" display-inline="no-display-inline" id="idd22bbab4-ceb5-444f-b264-c0ed1b136127"><enum>(I)</enum><text display-inline="yes-display-inline">the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id1078f43b-fc06-4dca-b79f-7c6c520632a6"><enum>(II)</enum><text display-inline="yes-display-inline">the excess facility percentage described in clause (iii).</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id782e4fea-7cda-42fb-b6ac-37ab8cfe23e3"><enum>(iii)</enum><header>Excess facility percentage</header><text display-inline="yes-display-inline">The excess facility percentage described in this clause is—</text><subclause commented="no" display-inline="no-display-inline" id="idf7a338bd-6ab7-4604-9435-c7868f00115a"><enum>(I)</enum><text display-inline="yes-display-inline">the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id3cf9cba9-3c7b-4aae-b853-373c79c938b0"><enum>(II)</enum><text display-inline="yes-display-inline">1,625.</text></subclause></clause></subparagraph></paragraph><paragraph display-inline="no-display-inline" id="idf5eeb608-2220-4342-9d42-2493e329cce6"><enum>(5)</enum><header>Annual fee setting</header><text>The Secretary shall, not later than 60 days before the first day of each fiscal year—</text><subparagraph commented="no" display-inline="no-display-inline" id="id70adff8f-393f-4855-9db0-9af88f3fd67c"><enum>(A)</enum><text>establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—</text><clause commented="no" display-inline="no-display-inline" id="idc831289d-d163-45a7-abfe-5adf60c1c1f4"><enum>(i)</enum><text display-inline="yes-display-inline">OTC monograph drug facility fees under subsection (a)(1); and</text></clause><clause commented="no" display-inline="no-display-inline" id="id83360bf7-6387-4c7f-9d18-7ef665e83f29"><enum>(ii)</enum><text>OTC monograph order request fees under subsection (a)(2); and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7eaf4fbd-f189-4570-818a-de5391f5ffd0"><enum>(B)</enum><text display-inline="yes-display-inline">publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id29b68c1e-c4bb-4e27-b5bb-e22cf1442b65"><enum>(d)</enum><header>Crediting and availability of fees</header><text>Section 744M(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(f)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id6839fb5b-f688-410a-8808-2e20da80345d"><enum>(1)</enum><text>in paragraph (2)(D)—</text><subparagraph commented="no" display-inline="no-display-inline" id="idc175dfc4-1977-4737-a441-23cf8817778e"><enum>(A)</enum><text>in the subparagraph heading, by striking <quote><header-in-text level="subparagraph" style="OLC">in subsequent years</header-in-text></quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id6f26941d-d0b8-4f6a-a0f8-e528599fb070"><enum>(B)</enum><text>by striking <quote>(after fiscal year 2021)</quote>; and</text></subparagraph></paragraph><paragraph id="id0dc4678e-1bb7-4538-99b9-f1e9fb46ce64"><enum>(2)</enum><text>in paragraph (3), by striking <quote>2021 through 2025</quote> and inserting <quote>2026 through 2030</quote>.</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="ideab9af27-0c1f-4fe4-820d-63ac37cdf29f" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>5.</enum><header>Reauthorization; reporting requirements</header><subsection commented="no" display-inline="no-display-inline" id="id966585f62b8b47ae8d41f77be719b833"><enum>(a)</enum><header display-inline="yes-display-inline">Performance report</header><text display-inline="yes-display-inline">Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id94c40687-d3bd-4371-af65-05bd0cffdebe"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph commented="no" display-inline="no-display-inline" id="idf68594c5-e3d0-4803-b666-ecc482538f33"><enum>(A)</enum><text>by striking <quote>Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter</quote> and inserting the following: </text><quoted-block style="OLC" display-inline="no-display-inline" id="id420622cc8d204ed78d2602140f96adea" changed="added" reported-display-style="italic" committee-id="SSHR00"><paragraph id="id1a7427e64a814fd7ac52f04c03b27d0c"><enum>(1)</enum><header>In general</header><text>Not later than 120 calendar days after the end of each fiscal year</text></paragraph><after-quoted-block>; </after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id8e6f69e5-e1cf-499f-9219-72f42f5ca768"><enum>(B)</enum><text>by striking <quote>section 3861(b) of the CARES Act</quote> and inserting <quote>section 2 of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5f2a57f67d814de896b732c23095c6ed"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="iddb23125f30804e6e978fb6ecaa71520a" changed="added" reported-display-style="italic" committee-id="SSHR00"><paragraph id="id2b626feb60814d728e9f6b90166c57d8"><enum>(2)</enum><header>Additional information</header><text>Beginning with fiscal year 2026, the annual report under this subsection shall include—</text><subparagraph commented="no" display-inline="no-display-inline" id="idfe6d132cac1a43d4bea33409aaea71bf"><enum>(A)</enum><text display-inline="yes-display-inline">the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—</text><clause commented="no" display-inline="no-display-inline" id="id5af8a33cd997492dbc07e0e51187f46c"><enum>(i)</enum><text display-inline="yes-display-inline">the number of Tier 1 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text></clause><clause commented="no" display-inline="no-display-inline" id="id1a90edffdbf44904aca6864122ff3e8b"><enum>(ii)</enum><text display-inline="yes-display-inline">the number of Tier 2 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text></clause><clause commented="no" display-inline="no-display-inline" id="id9f252c2007fb4c1a804b09f6aece5c84"><enum>(iii)</enum><text display-inline="yes-display-inline">the number of specified safety OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year; </text></clause><clause commented="no" display-inline="no-display-inline" id="id47a6ee234e2840b99337897e5c0c1fba"><enum>(iv)</enum><text display-inline="yes-display-inline">the number of generally recognized as safe and effective finalization OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;</text></clause><clause commented="no" display-inline="no-display-inline" id="id3ebf8c9599104ce5bbe4277fc69f0f45"><enum>(v)</enum><text display-inline="yes-display-inline">the average timeline for processing OTC monograph order requests, in the aggregate and by submission type, in the previous fiscal year; and</text></clause><clause id="ida0c458a24a1441e1a4fa27eeb6ae388f"><enum>(vi)</enum><text>postmarket safety activities with respect to OTC monograph drugs, including— </text><subclause commented="no" display-inline="no-display-inline" id="idf58671b500904665bead05c4dc58c0b2"><enum>(I)</enum><text display-inline="yes-display-inline">collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id319b79ec7bd149d0811d5d46dd271c99"><enum>(II)</enum><text display-inline="yes-display-inline">developing and using improved analytical tools, adverse event data-collection systems, including information technology systems, to assess potential safety problems, including access to external databases; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="idc07bbae92b0d47e0be7a0baa1581d718"><enum>(III)</enum><text>activities under section 760;</text></subclause></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id839790f2d2c84531bf3671df41b8a244"><enum>(B)</enum><text>information regarding registration of OTC monograph drug facilities and contract manufacturing organization facilities and payment of registration fees by such facilities, including—</text><clause commented="no" display-inline="no-display-inline" id="ide5549a9e0286437f81c207bed8535fc7"><enum>(i)</enum><text display-inline="yes-display-inline">the OTC monograph drug facilities and contract manufacturing organization facilities that were first registered under section 510(c) or 510(i) in the fiscal year; and</text></clause><clause commented="no" display-inline="no-display-inline" id="id4171de0ea9d943bd8bea4fa679f019a3"><enum>(ii)</enum><text display-inline="yes-display-inline">for each OTC monograph drug facility and contract manufacturing organization facility that was assessed a facility fee under section 744M(a) in the fiscal year, whether the facility paid such fee; </text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id330949ed5b3f40eeba46cb96b9fbfbb5"><enum>(C)</enum><text>the status of implementation of evidence and testing standards for nonprescription drugs intended for topical administration, including—</text><clause id="id17aa4bb2cc8a42b78d7bf6ee2660cc7b"><enum>(i)</enum><text display-inline="yes-display-inline">the application of evidence or testing standards; and</text></clause><clause id="id1f34c42c51764edfb72432f21c888f73"><enum>(ii)</enum><text>the number of active ingredient requests for nonprescription drugs intended for topical administration reviewed using the standards under section 505G(b); and</text></clause></subparagraph><subparagraph id="id32cc8064c685438d83961ae403406801"><enum>(D)</enum><text>the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1c67a464c7f84df0ac105a6d115acb2c"><enum>(3)</enum><header>Confidentiality</header><text display-inline="yes-display-inline">Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code.</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3204cc8c-b73c-4d68-b0fc-b3b67919f25e"><enum>(2)</enum><text>in subsection (b), by striking <quote>fiscal year 2021 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id35d17bcf-990d-405d-933d-cc8235759d3b"><enum>(3)</enum><text>in subsection (d)—</text><subparagraph commented="no" display-inline="no-display-inline" id="idbd86e3a8d9b84272b7542200447af9c2"><enum>(A)</enum><text display-inline="yes-display-inline">by striking <quote>2025</quote> each place it appears and inserting <quote>2030</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id843d61d9802d4a11aa55f18ac1ab5796"><enum>(B)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idaacf4ab40e1a4d7ba1514d250b97fdc4" changed="added" reported-display-style="italic" committee-id="SSHR00"><paragraph id="ID3E07D73433E345109FD94AC8D201FA1E" commented="no" display-inline="no-display-inline"><enum>(4)</enum><header display-inline="yes-display-inline">Minutes of negotiation meetings</header><subparagraph id="ID6D73F2D1C95540A9B2C7E3BF53A15DD0" commented="no" display-inline="no-display-inline"><enum>(A)</enum><header>Public availability</header><text>The Secretary shall make publicly available, on the public website of the Food and Drug Administration, robust written minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the regulated industry, not later than 30 days after each such negotiation meeting.</text></subparagraph><subparagraph id="IDD1E5D08F10C8408BA3774F6E5F15DCA3" commented="no" display-inline="no-display-inline"><enum>(B)</enum><header>Content</header><text>The robust written minutes described under subparagraph (A) shall contain, in detail, any substantive proposal made by any party to the negotiations as well as significant controversies or differences of opinion during the negotiations and their resolution.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="idb6aa6f74af684d3f9cbdd7ac331ee67e"><enum>(b)</enum><header>GAO report</header><paragraph id="id7c5bc9bd098746ac847d5254f7f551d6"><enum>(1)</enum><header>In general</header><text>Not later than September 30, 2027, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report assessing the supply chain of over-the-counter monograph drugs.</text></paragraph><paragraph id="id82da79282d9e4ed2bad8499bf22ba2f8"><enum>(2)</enum><header>Contents</header><text>The report required under paragraph (1) shall include an assessment of—</text><subparagraph id="id3ef8a72879344385b2492547c7ce6396"><enum>(A)</enum><text>the overall stability of the supply chain of over-the-counter monograph drugs;</text></subparagraph><subparagraph id="id1402e8bbf2f44ff9bccd9f5d74ee007d"><enum>(B)</enum><text>what information is collected by the Food and Drug Administration with respect to the supply chain of over-the-counter monograph drugs;</text></subparagraph><subparagraph id="id208bd2a477ea4c29a911ff72f6a1b13d"><enum>(C)</enum><text>how the Food and Drug Administration uses information collected on the supply chain of over-the-counter monograph drugs to inform regulatory decisions;</text></subparagraph><subparagraph id="idafd698f3b7664410973e8a58b27cdf90"><enum>(D)</enum><text>how the Food and Drug Administration coordinates with other Federal agencies to monitor and mitigate disruptions to the supply chain of over-the-counter monograph drugs; and</text></subparagraph><subparagraph id="id697b1ea7a07b4ddbb4fc421b5f6f9602"><enum>(E)</enum><text>the unique characteristics of the over-the-counter monograph drug marketplace and what additional authorities or information the Food and Drug Administration may need to ensure the stability of the supply chain of over-the-counter monograph drugs.</text></subparagraph></paragraph></subsection></section><section id="H5070BA80C64246FE96A876D62FB5E9C0" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>6.</enum><header>Treatment of active ingredients for topical administration</header><subsection commented="no" display-inline="no-display-inline" id="id5c38ff7a5844419a95a5f9ed786d213a"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 505G of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H882EAE1A9437417AA30EE9A1CF5883D6" changed="added" reported-display-style="italic" committee-id="SSHR00"><subsection id="HAF9AF38DBB314E8D8299CD0A0D31998C"><enum>(r)</enum><header>Evidence and testing standards for active ingredients for topical administration</header><paragraph id="HBE0CE172B204445F865363F410C9EF52"><enum>(1)</enum><header>Evidence and testing standards for active ingredients for topical administration</header><text>The Secretary shall—</text><subparagraph commented="no" display-inline="no-display-inline" id="id1bd5fe5ca70d4384b05c1f0d0f0b3bce"><enum>(A)</enum><text display-inline="yes-display-inline">in evaluating the generally recognized as safe and effective status of active ingredients used in nonprescription drugs intended for topical administration for purposes of subsection (a), utilize standards that allow for the use of real world evidence (as defined in section 505F(b)), as appropriate, as part of a comprehensive evaluation of scientific evidence to demonstrate the safety and effectiveness of such active ingredients, to supplement evidence from traditional clinical trials, provided that such standards allow the Secretary to evaluate whether the benefits of such active ingredients outweigh the risks; and</text></subparagraph><subparagraph id="H2B3DEAE84BE34CD0AAE778C3817B7A7E"><enum>(B)</enum><text>apply subsection (b)(6)(C) to the regulation of active ingredients used in drugs intended for topical administration.</text></subparagraph></paragraph><paragraph id="H8BCDD37A6C754EB8B837D1923003C301"><enum>(2)</enum><header>Non-animal testing methods for topical active ingredients</header><subparagraph id="HD4593E4FC0A645A284D088EE55F9DB3B"><enum>(A)</enum><header>In general</header><text>The Secretary shall consider the types of nonclinical tests described in paragraphs (1) through (4) of the first subsection (z) of section 505 (as inserted by section 3209(a)(2) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>)), or any other alternative to animal testing that the Secretary determines appropriate, in the consideration of drugs intended for topical administration under this section.</text></subparagraph><subparagraph id="HA7B4C1F01FB44BAB92F6F9D1114973A7"><enum>(B)</enum><header>Guidance</header><text>Not later than 1 year after the date of enactment of this subsection, the Secretary shall issue new draft guidance on how sponsors can use nonclinical testing alternatives to animal testing, as appropriate, to meet safety and efficacy standards under this section for drugs intended for topical administration.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idec6ae93f168b475d8e5b9ddc95ca8da0"><enum>(3)</enum><header>Clarification</header><text display-inline="yes-display-inline">Nothing in this subsection shall be construed to alter, supersede, or limit the standards for making determinations of whether a drug is generally recognized as safe and effective under section 201(p) or the standards set forth under section 505 for determining the safety and effectiveness of drugs.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HC19F0FF3255E45E6A3220A8146D6BC0D"><enum>(b)</enum><header>Sunscreen final administrative order</header><text display-inline="yes-display-inline">A final administrative order on nonprescription sunscreen active ingredients issued under section 3854 of the Coronavirus Aid, Relief, and Economic Security Act (<external-xref legal-doc="public-law" parsable-cite="pl/116/136">Public Law 116–136</external-xref>; <external-xref legal-doc="usc" parsable-cite="usc/21/360fff-3">21 U.S.C. 360fff–3</external-xref> note) shall—</text><paragraph id="H778A91B1E9AD4EAC84E4650AD1065FD3"><enum>(1)</enum><text>account for historical data regarding the safety of sunscreen active ingredients that have previously been accepted for marketing in the United States;</text></paragraph><paragraph id="H8395D2DA47D5450B8C863BA46C3D1B0F"><enum>(2)</enum><text>account for the role of broad spectrum sunscreens with a Sun Protection Factor of 15 or higher in effective skin cancer prevention; and</text></paragraph><paragraph id="H181D93E8D2254945A5AE97F1EBC6BE83"><enum>(3)</enum><text display-inline="yes-display-inline">incorporate the evidence and testing standards for sunscreen active ingredients detailed in section 505G(r) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h</external-xref>) (as added by subsection (a)).</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id4f55cb53d8d540029eeed520636d54e2" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>7.</enum><header>Increasing the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches</header><subsection id="id340de576a571458491abba914b649a0e"><enum>(a)</enum><header>In general</header><text>Section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id64516a69bf3d43119f9ea2d510b38a34" changed="added" reported-display-style="italic" committee-id="SSHR00"><paragraph id="id68a3b87a56254cf38c6d04c9b3a25c19"><enum>(7)</enum><header>Rx-to-nonprescription switches</header><subparagraph commented="no" display-inline="no-display-inline" id="ide53902dd2718457c98cfe853fcada784"><enum>(A)</enum><header display-inline="yes-display-inline">Meetings</header><text>Any person planning to submit an application for an Rx-to-nonprescription switch may submit to the Secretary a written request for a meeting, for purposes of developing a plan for such application that addresses the potential risks to public health of such switch and the evidence necessary to support such application, including the design of any necessary studies, and the format and content of the planned application. The Secretary may grant such a meeting, as appropriate, consistent with established procedures for granting meetings with, and providing written responses to, sponsors of applications under this section. Each such meeting shall be documented in meeting minutes.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide3ab1f35abbb4edf8644bf6aea45c1c3"><enum>(B)</enum><header>Guidance</header><clause commented="no" display-inline="no-display-inline" id="ida2fd0c3fcfeb4291a4458f11885f5f56"><enum>(i)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this paragraph, the Secretary shall issue guidance to increase the clarity and predictability of the process and standards for approval of applications for nonprescription drugs under this section, including in the case of applications for an Rx-to-nonprescription switch, especially with respect to prescription drugs with well-established safety profiles for which an applicant may seek approval for nonprescription use.</text></clause><clause commented="no" display-inline="no-display-inline" id="id1166378f71b845e08364485c1ebd76e3"><enum>(ii)</enum><header>Contents</header><text display-inline="yes-display-inline">The guidance under clause (i) shall—</text><subclause commented="no" display-inline="no-display-inline" id="id5376280bfdea4ef49abfc993f6c80e0f"><enum>(I)</enum><text display-inline="yes-display-inline">describe how published reports in medical literature, any previous finding of safety or effectiveness for the drug under this section, the results of significant human experience with the drug, unpublished studies and other data, and other sources of information may be used to support an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id7011b6167cdd45a58a5ea060eb0f40cf"><enum>(II)</enum><text display-inline="yes-display-inline">set forth procedures for sponsors to request meetings described in subparagraph (A) and document the recommendations made in such meetings;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id371b582381ef4ce0a52b7cd8069849e3"><enum>(III)</enum><text display-inline="yes-display-inline">describe evidentiary expectations to support approval of an application for a nonprescription drug, including in the context of an application for an Rx-to-nonprescription switch, including how sponsors can demonstrate that consumers can appropriately self-select and use the drug and comprehend the nonprescription drug label; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id5ce269700707478daf2c996a1b2b72fa"><enum>(IV)</enum><text display-inline="yes-display-inline">provide recommendations for how mechanisms, in addition to the required Drug Facts Label, such as mobile applications and decision aids, can be incorporated into the information submitted in support of an application for an Rx-to-nonprescription switch.</text></subclause></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ida7f0d529abbf4bda999c04cc51d7d445"><enum>(C)</enum><header>Plan to engage with stakeholders</header><text>Not later than 1 year after the date of enactment of this paragraph, the Secretary shall develop and make publicly available on the website of the Food and Drug Administration a plan to engage stakeholders on steps and factors for application holders and other stakeholders to consider in identifying approved prescription drugs that may be promising candidates for applications for an Rx-to-nonprescription switch.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id91316aae89964c69a7838ce5ddc85c14"><enum>(D)</enum><header>Definition</header><text>The term <term>Rx-to-nonprescription switch</term> means the approval of an application, or supplemental application, as applicable, submitted under this section by the holder of an approved application for a prescription drug seeking approval to market such drug as a nonprescription drug, including for—</text><clause commented="no" display-inline="no-display-inline" id="id2ee1a46337764b6990f214340c7ca2bc"><enum>(i)</enum><text display-inline="yes-display-inline">a full Rx-to-nonprescription switch, under which a drug previously approved for prescription use only is—</text><subclause commented="no" display-inline="no-display-inline" id="idd2ee00a3ea2f4a269b36a43a1a6546cf"><enum>(I)</enum><text display-inline="yes-display-inline">approved for nonprescription use under the same conditions of use as applied to the drug when approved for prescription use; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="id0786e522017b4c91914bbaccd1dac0cf"><enum>(II)</enum><text>approved for nonprescription use subject to one or more additional conditions for nonprescription use; and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="id0a19c69a9c3e444daa49528cec166d00"><enum>(ii)</enum><text display-inline="yes-display-inline">a partial Rx-to-nonprescription switch, under which the drug is approved for nonprescription use only under certain conditions of use described in the approved labeling, while the drug otherwise remains approved for prescription use only.</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide0d43231b0ef4c328d4f9427a7d38fd4"><enum>(E)</enum><header display-inline="yes-display-inline">Rule of construction</header><text>Nothing in this paragraph shall be construed to—</text><clause commented="no" display-inline="no-display-inline" id="id2a1676a090f240b4814a2c25c072f499"><enum>(i)</enum><text>supersede or modify the authority of the Secretary under section 505G with respect to the regulation of OTC monograph drugs; or</text></clause><clause commented="no" display-inline="no-display-inline" id="id0a60804ec0924713a580fd96b410479a"><enum>(ii)</enum><text display-inline="yes-display-inline">authorize the disclosure by the Secretary of confidential commercial information or trade secrets.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="id0be49e5ec51944ebb9802bba71b93cbb"><enum>(b)</enum><header>GAO Report</header><paragraph commented="no" display-inline="no-display-inline" id="id68652bef954d4540bbf67478081dd3c4"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that evaluates—</text><subparagraph id="idac1db4d676074d40a02641bd96298acb"><enum>(A)</enum><text>the number of applications for an Rx-to-nonprescription switch approved during the period beginning on October 1, 2022, and ending on the date of the report;</text></subparagraph><subparagraph id="idfe22b2e370eb46ac9a46c1853fb35d95"><enum>(B)</enum><text>the number of drugs for which an application for an Rx-to-nonprescription switch was approved during such period subject to an additional condition for nonprescription use;</text></subparagraph><subparagraph id="ide3ebc1ca7d3d4a6ebbf3d0de51488b91"><enum>(C)</enum><text>among the drugs for which an application for a full or partial Rx-to-nonprescription switch was approved during such period, the average length of time from receipt by the Food and Drug Administration of the application to the approval of such application;</text></subparagraph><subparagraph id="id82e28a0bea0144debd626f5f4a77e405"><enum>(D)</enum><text>the number of partial Rx-to-nonprescription switch applications approved during such period, and the number of applications for such a partial switch was not approved;</text></subparagraph><subparagraph id="id01a8ed77bd114f5595f87082380203dc"><enum>(E)</enum><text>any barriers to timely and predictable review of applications for an Rx-to-nonprescription switch; </text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc1a4073aa42d48b691957daabee6ebe0"><enum>(F)</enum><text display-inline="yes-display-inline">engagement by the Food and Drug Administration with public stakeholders, including public meetings or additional activities, to support review of applications for an Rx-to-nonprescription switch; and</text></subparagraph><subparagraph id="id74d15ec853d84440a1d0546da7a73e10"><enum>(G)</enum><text>opportunities for collaboration between the Center for Drug Evaluation and Research and the Centers for Medicare &amp; Medicaid Services for the purpose of analyzing health insurance claims data for commonly prescribed drugs that appear to be suitable for an Rx-to-nonprescription switch.</text></subparagraph></paragraph><paragraph id="id893a8fde9b1247bca933e14bda6a1203" commented="no" display-inline="no-display-inline"><enum>(2)</enum><header>Definition</header><text>In this subsection, the term <term>Rx-to-nonprescription switch</term> has the meaning given such term in paragraph (7) of section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/244">21 U.S.C. 244(b)</external-xref>), as added by subsection (a).</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id00e3cde4-0ab6-4e06-8bd2-dff079c17dbd" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>8.</enum><header>Sunset dates</header><subsection id="idfcf15b50-91ed-4392-bd9b-53d30a3ae38f"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Sections 744L and 744M of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71</external-xref>; 379j–72) shall cease to be effective October 1, 2030. </text></subsection><subsection id="idb6964106-be6b-4936-8f90-f3c40ad58b05"><enum>(b)</enum><header>Reporting requirements</header><text>Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) shall cease to be effective January 31, 2031.</text></subsection></section><section id="id9ccefa81-d618-4b81-9e0c-b7ae7278c8ab" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>9.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this Act shall take effect on October 1, 2025, or the date of the enactment of this Act, whichever is later, except that fees under part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>) shall be assessed beginning October 1, 2025, regardless of the date of the enactment of this Act.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="ide5e8aeeb-2173-44a4-adbf-fa0972d76047" changed="added" reported-display-style="italic" committee-id="SSHR00"><enum>10.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this Act, part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>), as in effect on the day before the date of enactment of this Act, shall continue to be in effect with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2026.</text></section></legis-body><endorsement><action-date date="20250908">September 8, 2025</action-date><action-desc>Reported with an amendment</action-desc></endorsement></bill> 

